<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Asthma is a chronic and complex airway inflammatory disease characterized by airway hyperresponsiveness. Current asthma therapies are limited to specific disease manifestations, highlighting the importance of developing treatments with broader treatment applications. CD4+ T lymphocytes, which produce a characteristic repertoire of cytokines, play a critical role in the development of airway inflammation, mucus production, and airway hyper-responsiveness in asthma. Recently, it has been demonstrated that Heat Shock Protein 60 (HSP60) could mediate CD4+ T lymphocyte differentiation, suggesting that HSP60 can be targeted in the development of novel anti-asthma medications, especially for the treatment of severe disease or refractory patients. Objective: This review summarizes the current knowledge regarding the relationship between HSP60 and asthma. Method: We conducted a literature search using the MEDLINE (PubMed), SCOPUS and OVID/LWWW databases using the keywords “HSP”, “HSP60”, “HSP60 signaling pathway”, “TLR”, “TLR2 signaling pathway”, “asthma”, and “CD4+ T Lymphocytes”. Only articles published in English were included in the review. Results: HSP60 was shown to either inhibit or exacerbate asthma through different mechanisms. However, the deleterious effects of HSP60 on asthma likely surpassed any beneficial inhibitory effects. Conclusion: HSP60 can be expected to be developed into a new treatment target for asthma that may be of great interest to medical scientists and clinicians.</abstract>

Background: Asthma is a chronic and complex airway inflammatory disease characterized by airway hyperresponsiveness. Current asthma therapies are limited to specific disease manifestations, highlighting the importance of developing treatments with broader treatment applications. CD4+ T lymphocytes, which produce a characteristic repertoire of cytokines, play a critical role in the development of airway inflammation, mucus production, and airway hyper-responsiveness in asthma. Recently, it has been demonstrated that Heat Shock Protein 60 (HSP60) could mediate CD4+ T lymphocyte differentiation, suggesting that HSP60 can be targeted in the development of novel anti-asthma medications, especially for the treatment of severe disease or refractory patients. Objective: This review summarizes the current knowledge regarding the relationship between HSP60 and asthma. Method: We conducted a literature search using the MEDLINE (PubMed), SCOPUS and OVID/LWWW databases using the keywords “HSP”, “HSP60”, “HSP60 signaling pathway”, “TLR”, “TLR2 signaling pathway”, “asthma”, and “CD4+ T Lymphocytes”. Only articles published in English were included in the review. Results: HSP60 was shown to either inhibit or exacerbate asthma through different mechanisms. However, the deleterious effects of HSP60 on asthma likely surpassed any beneficial inhibitory effects. Conclusion: HSP60 can be expected to be developed into a new treatment target for asthma that may be of great interest to medical scientists and clinicians.

Heat shock protein 60 and asthma treatment 10.5372/1905-7415.0604.084

Department of Respiratory Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011,

Student Dormitory 9-102, Second Xiangya Hospital, Furong, Changsha, Hunan 410011, China

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Heat shock protein 60 and asthma treatment 10.5372/1905-7415.0604.084"}

Background: Asthma is a chronic and complex airway inflammatory disease characterized by airway hyperresponsiveness. Current asthma therapies are limited to...

Heat shock protein 60 and asthma treatment 10.5372/1905-7415.0604.084

Article Category: Review article

Published Online: Feb 04, 2017

Page range: 513 - 518

DOI: https://doi.org/10.5372/1905-7415.0604.084

Keywords
Asthma, CD4+ T Lymphocytes, HSP60

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Heat shock protein 60 and asthma treatment 10.5372/1905-7415.0604.084

Article Category: Review article

Published Online: Feb 04, 2017

Page range: 513 - 518

DOI: https://doi.org/10.5372/1905-7415.0604.084

KeywordsAsthma, CD4+ T Lymphocytes, HSP60

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Keywords
Asthma, CD4+ T Lymphocytes, HSP60